Combination of antiangiogenic RAD001 and ionizing radiation in therapy of malignant tumors

被引：0
|
作者：
Manegold, Philipp [1 ]
Paringer, Carmen [1 ]
Kulka, Ulrike [1 ]
Wilkowski, Ralf [1 ]
Jauch, Karl-Walter [1 ]
Guba, Markus [1 ]
Bruns, Christiane J. [1 ]
机构：
[1] Univ Munich Grosshadern, Munich, Germany
来源：
CANCER RESEARCH | 2006年 / 66卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4397
引用
收藏
页数：2
相关论文
共 50 条
  • [41] COMPARATIVE STUDY OF EFFECTS OF LASER AND/OR IONIZING RADIATION THERAPY ON EXPERIMENTAL OR HUMAN MALIGNANT TUMORS
    MCGUFF, PE
    GOTTLIEB, LS
    KATAYAMA, I
    LEVY, CK
    AMERICAN JOURNAL OF ROENTGENOLOGY RADIUM THERAPY AND NUCLEAR MEDICINE, 1966, 96 (03): : 744 - &
  • [42] A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer
    Moulder, Stacy
    Gladish, Gregory
    Ensor, Joe
    Gonzalez-Angulo, Ana Maria
    Cristofanilli, Massimo
    Murray, James L.
    Booser, Daniel
    Giordano, Sharon H.
    Brewster, Abeena
    Moore, Julia
    Rivera, Edgardo
    Hortobagyi, Gabriel N.
    Tran, Hai T.
    CANCER, 2012, 118 (09) : 2378 - 2384
  • [43] Results of a phase I study of RAD001 in combination with lenalidomide in patients with relapsed or refractory multiple mycloma
    Mahindra, A. K.
    Richardson, P. G.
    Hari, P.
    Laubach, J.
    Ghobrial, I. M.
    Schlossman, R. L.
    Weller, E.
    Munshi, N. C.
    Anderson, K. C.
    Raje, N. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [44] The mammalian target of rapamycin inhibitor RAD001 (everolimus) synergizes with chemotherapeutic agents, ionizing radiation and proteasome inhibitors in pre-B acute lymphocytic leukemia
    Saunders, Philip
    Cisterne, Adam
    Weiss, Jocelyn
    Bradstock, Kenneth F.
    Bendall, Linda J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2011, 96 (01): : 69 - 77
  • [45] Targeted therapy in Multiple Myeloma: Results of first phase I study with everolimus (RAD001)
    Guenther, A.
    Baumann, P.
    Burger, R.
    Klapper, W.
    Schmidmaier, R.
    Gramatzki, M.
    ONKOLOGIE, 2010, 33 : 94 - 94
  • [46] Combination antiangiogenic therapy and radiation in head and neck cancers
    Hsu, Heng-Wei
    Wall, Nathan R.
    Hsueh, Chung-Tsen
    Kim, Seungwon
    Ferris, Robert L.
    Chen, Chien-Shing
    Mirshahidi, Saied
    ORAL ONCOLOGY, 2014, 50 (01) : 19 - 26
  • [47] Antiangiogenic Therapy for Malignant Brain Tumors: Does It Still Matter?
    Pellerino, Alessia
    Bruno, Francesco
    Soffietti, Riccardo
    Ruda, Roberta
    CURRENT ONCOLOGY REPORTS, 2023, 25 (07) : 777 - 785
  • [48] A phase I-II study of everolimus (RAD001) in combination with imatinib in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (GIST)
    Dumez, H.
    Reichard, P.
    Blay, J. Y.
    Schoeffski, P.
    Morgan, J. A.
    Ray-Coquard, I. L.
    Hollaender, N.
    Jappe, A.
    Demetri, G. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [49] Antiangiogenic Therapy for Malignant Brain Tumors: Does It Still Matter?
    Alessia Pellerino
    Francesco Bruno
    Riccardo Soffietti
    Roberta Rudà
    Current Oncology Reports, 2023, 25 : 777 - 785
  • [50] SWOG 0722: A phase II study of mTOR inhibitor everolimus (RAD001) in malignant pleural mesothelioma (MPM).
    Garland, Linda L.
    Ou, Sai-Hong
    Moon, James
    Mack, Philip C.
    Testa, Joseph
    Tsao, Anne S.
    Wozniak, Antoinette J.
    Gandara, David R.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345